Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

GATA-4, a potential novel therapeutic target for high-grade meningioma, regulates miR-497, a potential novel circulating biomarker for high-grade meningioma

15 Aug 2020

Abstract excerpt

BACKGROUND: Meningiomas are the most common primary intracranial tumours. They are classified as grade I, II, and III based on their histopathological features. While most meningiomas can be managed by surgery alone, adjuvant treatment may be required in case of recurrent, or high-grade tumours. To date, chemotherapy has proven ineffective in meningioma patients, reinforcing the need for novel therapeutic targets...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glioma Diagnosis and Treatment
Share to Meningioma and schwannoma management
Share to MicroRNA in disease regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32810829
DOI: 10.1016/j.ebiom.2020.102941

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

GATA-4, a potential novel therapeutic target for high-grade meningioma, regulates miR-497, a potential novel circulating biomarker for high-grade meningiomaPMID 32810829Read ↗

The biological and diagnostic roles of MicroRNAs in meningiomasSemantic proximity Read ↗

Investıgatıon of The Dıagnostıc and Prognostıc Values of Some Specıfıc mıcroRNAs In Menıngıom TumorsSemantic proximity Read ↗

Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomasSemantic proximity Read ↗

Skull base invasive low-grade meningiomas, a distinct genetic subgroup: A microarray gene expression profile analysisSemantic proximity Read ↗

Identification of PD-L2, B7-H3 and CTLA-4 immune checkpoint proteins in genetic subtypes of meningiomaSemantic proximity Read ↗

A microRNA expression signature predicts meningioma recurrenceSemantic proximity Read ↗

Genome-wide analysis reveals prognostic value of novel signature CLU for malignant meningioma patients based on large-scale cohortsSemantic proximity Read ↗

Downregulated MicroRNA-200a in Meningiomas Promotes Tumor Growth by Reducing E-Cadherin and Activating the Wnt/β-Catenin Signaling PathwaySemantic proximity Read ↗

Posttranscriptional deregulation of signaling pathways in meningioma subtypes by differential expression of miRNAsSemantic proximity Read ↗

miR-153-5p suppresses the proliferation, invasion and migration of malignant meningioma via the MEK/ERK signaling pathway by targeting GAB1Semantic proximity Read ↗

Decoding meningioma heterogeneity and neoplastic cell—macrophage interaction through single-cell transcriptome profiling across pathological gradesSemantic proximity Read ↗

Comparative Protein Profiling Reveals Minichromosome Maintenance (MCM) Proteins As Novel Potential Tumor Markers for MeningiomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.